IMPORTANCE Laryngotracheal stenosis (LTS) is a fibroproliferative disorder of the glottis, subglottis, and trachea. In models of fibrosis from other organ systems, the CD4 + T-cell response has been shown to regulate extracellular matrix deposition. Specifically, helper T cell 2 (T H 2) promotes fibrosis, whereas T H 1 and associated cytokines have been shown to be antifibrotic. However, this antifibrotic effect of the T H 1 response has not been demonstrated in LTS.
L aryngotracheal stenosis (LTS) is a critical narrowing of the glottis, subglottis, and/or trachea secondary to the development of pathologic fibrosis or scar. Laryngotracheal stenosis is most commonly a result of postintubation injury but can also be autoimmune related, radiation induced, or idiopathic. 1, 2 The multiple consequences of LTS include communication handicap and airway obstruction, a potentially life-threatening complication if not managed appropriately. 1, 3 The contemporary management of LTS is primarily surgical and includes serial dilation, tracheal or cricotracheal resection, laryngotracheoplasty, and/or permanent tracheostomy. 4, 5 Medical therapies available for the management of LTS are limited, reflecting a need for improved understanding of disease pathogenesis. The pathologic fibrosis observed in LTS has been attributed to aberrant wound healing and unregulated tissue remodeling 6 ; however, the molecular and immunologic mechanisms of this process remain to be fully elucidated. Fibroblasts, which are the main effector cell in fibrosis, have been demonstrated to be hypermetabolic and display a profibrotic phenotype in LTS. 7, 8 Although aberrant fibroblast function is ultimately responsible for the deposition of excessive collagen in LTS, the phenotypic changes observed in these fibroblasts has been proposed to be mediated by an adaptive immune mechanism. 9,10 In a murine model of subglottic stenosis, aberrant wound healing and the development of stenosis was mediated by circulating lymphocytes. 9 Furthermore, CD4 + T-cell-related cytokines have been shown to be elevated in biopsy samples from human LTS scar, thus implicating a potential role for this specific arm of T-cell immunity in the pathogenesis of LTS.
11
The role of the CD4 + T-cell immune response in fibrosis has been more clearly defined in other fibrotic diseases. Specifically, the differentiation of CD4 + T cells into a helper T cell 1
(T H 1) or T H 2 lineage has been shown to regulate fibrosis.
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In idiopathic pulmonary fibrosis (IPF), a fibroproliferative disease characterized by deposition of excessive collagen in the interstitial space, levels of the T H 1 cytokine interferon-γ (INF-γ) have been shown to be significantly reduced, whereas levels of the T H 2-related cytokines interleukin 4 (IL-4) and IL-13 are elevated. 15, 16 In addition, when CD4 + cells are skewed toward the T H 2 phenotype, increased expression of profibrotic genes not observed with the T H 1 phenotype is noted. 17 In systemic sclerosis, a diffuse fibrotic disease affecting the skin and organs, upregulated T H 2 cytokines have been demonstrated.
18
Alternatively, studies have shown that increasing the T H 1re-sponse can mediate an antifibrotic effect 19, 20 and, in a model of IPF, has been shown to suppress collagen production and subsequent fibrosis. 21 Cumulatively, these studies indicate that the deposition of excessive collagen, the hallmark of fibrotic disease, may share a common immunologic mechanism by which an imbalance between the T H 1 and T H 2 responses promotes pathologic fibrosis. 22 Given that LTS is a fibroproliferative disorder, therapy aimed at increasing the T H 1 response or that of its related cytokines may be an effective strategy for inhibiting the propagation of disease. However, immune stimulation has not been explored in LTS, and whether the antifibrotic effects of the T H 1 axis can be mediated through direct cytokine signaling alone remains unclear.
The critical role of fibroblast proliferation and collagen deposition in the development of LTS and the known hyperfunctional phenotype of LTS-derived fibroblasts makes them an ideal cell line for in vitro analysis. With use of LTS-derived fibroblasts, the influence of cytokine stimulation on LTSrelated fibrosis can be quantified in vitro. The goal of this investigation was to determine whether treatment with the T H 1 cytokine INF-γ can inhibit LTS-derived fibroblast function. Using an in vitro system of fibroblast culture, we assessed the association of INF-γ with fibroblast proliferation, histologic features, collagen production, and expression of fibrosis-related genes. This study provides an improved understanding of immunologic regulation of the fibroblasts responsible for LTS and potential therapeutic information about T H 1-based immunotherapy in LTS.
Methods

Fibroblast Isolation and Culture
Biopsy specimens of human laryngotracheal scar and normalappearing areas of the airway were procured during routine surgical dilation of subglottic and tracheal stenosis in 6 patients with iatrogenic LTS. All specimens used in this study were incidentally obtained from female patients with iatrogenic LTS, and sex was not a selection criterion. All patients had a history of prolonged intubation (eTable in the Supplement). Control groups in this study consisted of fibroblasts isolated from normal-appearing airway (normal airway fibroblasts) and fibroblasts isolated from areas of laryngotracheal scar (LTS fibroblasts). The experimental group consisted of LTS fibroblasts treated with INF-γ. This study was approved by the institutional review board of Johns Hopkins University. All patients provided written informed consent.
Data were collected from August 2015 through June 2016. Fresh tissue specimens were processed and fibroblasts were isolated and grown in fibroblast growth medium (Dulbecco modified Eagle medium; Gibco) supplemented with 10% fetal bovine serum (HyClone; Thermo Scientific), 100 U/mL penicillin (Gibco), 100 μg/mL streptomycin (Gibco), and nonessential amino acids (Gibco) at 37°C in a 5% carbon dioxidehumidified atmosphere as previously described. 7 Fibroblasts were characterized in vitro using immunohistochemical staining. Fibroblasts were identified by positive staining with a monoclonal rat antibody specific for an unknown antigen
Key Points
Question Can the helper T cell 1 cytokine interferon-γ inhibit laryngotracheal stenosis-derived fibroblasts in vitro?
Findings Interferon-γ reduced proliferation and collagen expression and production in laryngotracheal stenosis-derived fibroblasts while also reducing the expression of the profibrotic cytokine transforming growth factor β.
Meaning Immunomodulatory strategies that focus on increasing interferon-γ may be able to attenuate the progression of laryngotracheal stenosis.
present in fibroblasts called ER-TR7 (Santa Cruz Biotechnology Inc) and negative staining against the epithelial markers pan cytokeratin and AE1/AE3 using a monoclonal mouse antihuman pan cytokeratin antibody (Becton Dickenson) and a monoclonal mouse anti-AE1/AE3 antibody (Ventana Medical Systems). In addition, negative staining for the vascular endothelial marker ETS-related gene (ERG) was confirmed using a monoclonal mouse anti-ERG vascular antibody (Biocare Medical) and for the muscle-specific marker desmin using a monoclonal mouse antihuman desmin antibody (Agilent Technologies). 7 Fibroblasts were limited to passages 2, 3, and 4 for all experiments in this study. All studies were conducted in triplicate except cell proliferation, which was conducted in duplicate.
Cell Proliferation by Cell Count
Once confluent, adherent LTS-derived fibroblasts and normal airway fibroblasts underwent trypsinization, and 5000 cells were passaged into each well of a 6-well plate (Falcon; BD Biosciences). Cells were grown under the following conditions: (1) control in fibroblast growth media or (2) experimental in fibroblast growth media supplemented with 10 ng/mL of INF-γ (Abcam), resulting in a specific activity of 200 U/mL, a previously described dose correlating with minimum treatment concentrations of INF-γ in vivo. 19, 23 Media was aspirated and replaced with the same conditions 1 day after initial seeding. Cells were harvested from 1 well each day for 6 days; a mean total cell count was determined for each condition on each day using a hemocytometer. All proliferation studies were conducted in duplicate as previously described.
7,8
Cell Staining and Histologic Evaluation
The LTS-derived fibroblasts were cultured in control and experimental medium conditions for 3 days on microscope glass coverslips pretreated with a 0.1% gelatin solution. After 3 days, all glass coverslips were fixed with 10% formalin and stained with Masson trichrome. Microscopic images of the stained sections were obtained with a microscope (AX10; Zeiss) at 20 × magnification.
Gene Expression Analysis by Quantitative Real-Time Polymerase Chain Reaction
The LTS-derived and normal airway fibroblasts were seeded in 6-well culture plates (Falcon; BD Biosciences) with 250 000 cells per well and were grown in control and experimental medium conditions for 72 hours. Cells were harvested and RNA was extracted using a specialized kit (RNeasy Micro Kit; Qiagen) and then quantified using a spectrophotometer (NanoDrop 2000; Thermo Scientific). We used RNA for the creation of complementary DNA, and gene expression was quantified using quantitative real-time polymerase chain reaction (RT-PCR) as previously described. 10 The cycle threshold value (CT) of the genes of interest were normalized against β-actin (ΔCT) for all samples and then compared with expression in normal airway fibroblasts (ΔΔCT). Gene expression is presented as the relative fold change calculated by 2 −ΔΔCT . All samples were investigated in biological triplicate. Gene expression was quantified for the fibrosis-related genes colla- 
Assay for Soluble Collagen Quantification
The LTS-derived and normal airway fibroblasts were seeded in 6-well plates at a concentration of 250 000 cells per well in control media. After 24 hours, media were aspirated and replaced with control or experimental media. Cells were incubated for 96 hours, and soluble collagen content was quantified using a commercial collagen dye-binding assay (Sircol; Biocolor Ltd). Before quantification, collagen in the extracted media was concentrated using the concentration reagent. Concentrated collagen was mixed with the sirius red dye reagent for 30 minutes and then centrifuged at 12 000g. The remaining dye was aspirated, and the collagen-dye complex was washed. Collagen-bound dye was released in alkali reagent. Spectrophotometric measurement was determined at 555 nm using a microplate reader (Synergy2; BioTek), and total soluble collagen was quantified based on a standard curve.
Statistical Analysis
Results are displayed as means and 95% CIs of the mean difference. Differences between treatment and control groups were compared using a nonparametric Wilcoxon signed rank test. A 2-sided P < .05 was considered statistically significant. Data analysis was performed using Prism GraphPad statistical software. 
Results
LTS Fibroblast Proliferation
Collagen Expression and Deposition in LTS Fibroblasts
Gene expression analysis using quantitative RT-PCR demonstrated a reduction in COL1 and COL3 gene expression in INF-γ-treated, LTS-derived fibroblasts from all 6 patient samples. Overall, we found a 5.51-fold reduction in COL1 expression (95% CI, 3.31-9.15) (86% reduction) and a 3.07-fold reduction in COL3 expression (95% CI, 1.99-4.72) (68% reduction) in LTS-derived fibroblasts treated with INF-γ compared with untreated LTS-derived fibroblasts (Figure 2) . In addition, INF-γ treatment reduced soluble collagen production in all 6 LTS-derived fibroblast cell lines ( Figure 3A) . When compared as a group, this change resulted in a significant reduction in soluble collagen production in LTS-derived fibroblasts treated with INF-γ compared with untreated LTS fibroblasts (10.94 vs 14.89 μg/mL; mean difference, 3.950 μg/mL; 95% CI, −4.753 to −1.419 μg/mL) ( Figure 3B ). With use of the Masson trichrome stain, which stains collagen blue, in vitro collagen deposition by LTS-derived fibroblasts grown in control and INF-γ-treated media was demonstrated (Figure 4) .
TGF-β Expression in LTS Fibroblasts
Quantitative RT-PCR analysis demonstrated a 32% reduction in TGFB1 gene expression in all 6 patients (fold change, 0.68; 95% CI, 0.49-0.96) and a 24% reduction in TGFBR1 gene expression (fold change, 0.76; 95% CI, 0.42-1.37) in INF-γ-treated LTS fibroblasts compared with controls ( Figure 5 ). In addition, we found a 37% reduction in the expression of FN1 when LTS-derived fibroblasts were treated with INF-γ (fold change, 0.63; 95% CI, 0.34-1.16) and a minimal 6% reduction in ACTA2 expression (fold change, 0.94; 95% CI, 0.36-2.53) after treatment ( Figure 5 ).
Discussion
Laryngotracheal stenosis is a chronic and debilitating fibroproliferative disease characterized by luminal narrowing of the airway secondary to a chronic inflammatory response that promotes increased fibroblast activity, collagen deposition, and the formation of pathologic scar. The specific nature of this profibrotic inflammatory response may be related to an anomalous CD4 + T-cell response. In our study, we revealed the potent antifibrotic effects of the T H 1 cytokine INF-γ on LTS-derived fibroblasts by demonstrating significant reductions in fibroblast proliferation, fibrosis-related gene expression, and collagen production after INF-γ treatment. These results indicate that the fibroblasts associated with LTS scar formation can be inhibited by INF-γ signaling.
In the present study, INF-γ was used as an in vitro surrogate for assessing the effects of T H 1 signaling on LTS-derived fibroblasts, the primary effector cell in LTS. Although this in vitro system only captures the effects of 1 cytokine and does not reflect the complex cell-cell signaling network involved in an in vivo system, it provides a concise assessment of the association of the primary T H 1 cytokine with the fibroblasts responsible for potentiating fibrosis and scar formation in LTS. Given the central role of INF-γ in the T H 1 response, the reduction in fibroblast activity demonstrated in this study indi- dysregulated CD4 + T-cell response characterized by a defective T H 1 and predominant T H 2 response has been demonstrated. 25, 26 In recurrent respiratory papillomatosis, the inability to mount an effective T H 1 response has been hypothesized to promote recurrence and papilloma growth. Therefore, treatment strategies, including the use of intralesional mumps and bacillus Calmette-Guerin vaccination that stimulate the T H 1 response, have been explored and may represent potential therapies in LTS. 27, 28 In the present study, INF-γ manifests as a cytokine capable of inhibiting collagen production and mitigating the development of fibrosis.
12,19-21 However, despite these robust antifibrotic effects of INF-γ, it is unlikely to be a suitable systemic therapeutic for LTS secondary to a host of poorly tolerated constitutional symptoms, including fever, chills, myalgia, and vomiting. In addition, the systemic use of INF-γ in the treatment of IPF failed to demonstrate a survival benefit. 29-32 Alternatively, therapies that aim to increase INF-γ through immunomodulation of the CD4 + T-cell response with a focus on increasing T H 1 T-cell populations may prove to be more beneficial.
As previously mentioned, the use of vaccine-based immunotherapy can induce a T H 1 response and in IPF, its use demonstrated the potential to reverse the progression of fibrosis and improve disease status. 24 Immunomodulatory strategies such as this that increase the T H 1 response, have not been explored in LTS but, based on the findings in this study, may be beneficial. In addition, although this particular strategy focuses on stimulating the T H 1 response, other strategies focused on reducing the T H 2 response may also prove to be effective but have not yet been explored. The present study also demonstrated that TGFB1 gene expression in LTS fibroblasts was significantly reduced with INF-γ treatment. Transforming growth factor β is a profibrotic cytokine secreted by numerous cell types, including fibroblasts, and is associated with increased collagen deposition and fibrosis. 33 In LTS, increased TGF-β has been identified in biopsy specimens of stenosis, 34 justifying preclinical attempts at therapeutic inhibition of TGF-β. 35, 36 However, the ubiquitous nature of TGF-β and likely the need to inhibit the activated form have limited the clinical application of TGF-β inhibition. 37 However, the reduction of TGFB1 expression in this study may indicate that TGF-β is a surrogate marker for fibrosis. In addition, the antifibrotic effects of INF-γ treatment on LTSderived fibroblasts may be mediated through inhibition of TGFB1 gene expression because previous in vitro studies have demonstrated that INF-γ was unable to antagonize TGF-β directly. 38 Although these inferences represent interesting explanations for the interactions of INF-γ and TGF-β, additional studies are needed to delineate a relationship.
Limitations
Although this study demonstrates an antifibrotic effect for INF-γ on human LTS-derived fibroblasts, it has several limitations. The effects demonstrated in isolated cell culture in this in vitro study may not be reflective of the effects in vivo. In addition, disease mechanisms in LTS and its underlying immunopathologic features are not completely understood, and some inferences are being made based on more clearly defined fibrotic diseases, which may not reflect the true pathogenesis of LTS. Finally, the heterogeneity of LTS in regard to its severity and etiology may represent variable phenotypes and mechanisms of pathogenesis. Given these differences, immunologic signaling pathways in fibroblast-associated idiopathic LTS may be different from those in iatrogenic LTS and therefore may not demonstrate the same response to INF-γ treatment. Nonetheless, the antifibrotic effect of INF-γ in this study is encouraging and provides some evidence that the T H 1 response may be able to attenuate iatrogenic LTS pathogenesis; stimulation of this response could represent an effective treatment strategy for LTS.
Conclusions
Interferon-γ inhibited LTS-derived fibroblast proliferation, gene expression, and function in vitro. In addition, the observed antifibrotic effects of INF-γ may be mediated through a reduction in TGFB1 gene expression. The inhibitory effect of INF-γ on LTS-derived fibroblasts and its role in the T H 1 response suggest that shifting the T H 1-T H 2 balance may represent a potential immunologic strategy for disease modulation in LTS. Future in vivo studies are needed to delineate this immunologic mechanism in LTS so that targeted medical therapies can be investigated.
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